Cargando…
A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
Anamorelin (ANA) is approved for treating cancer cachexia (CCX) in Japan. We report the case of a 69-year-old man with stage IVB squamous cell lung cancer complicated by CCX, having a 13.6% weight loss in 6 months. After chemotherapy was initiated, his weight was further reduced. Therefore, we start...
Autores principales: | Oshima, Yuri, Matsuura, Hiroyuki, Sakurai, Yusuke, Hirai, Kaho, Tani, Eriko, Yoshimoto, Naoki, Minami, Kenichi, Yamasaki, Fumio, Nishime, Mayu, Hirashima, Tomonori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866093/ https://www.ncbi.nlm.nih.gov/pubmed/35242522 http://dx.doi.org/10.1016/j.rmcr.2022.101609 |
Ejemplares similares
-
A case of renal cell carcinoma with late recurrence in the bilateral hilar lymph nodes twenty years after surgery
por: Sakurai, Yusuke, et al.
Publicado: (2022) -
Acromegaly Initially Presenting with Severe Infectious Diseases: A Case Report
por: Tani, Eriko, et al.
Publicado: (2021) -
Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023) -
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022) -
Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)